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Research in context 
 
Evidence before this study 
The burden of life-threatening infections on childhood morbidity and mortality persists 
in spite of the substantial reduction in vaccine-preventable invasive bacterial infections 
since the introduction of conjugate vaccines in childhood, and the availability of 
antimicrobial agents.  
We carried out comprehensive and focused reviews of the scientiﬁc literature published 
between 2000 and July 2017, on severe childhood infections. For this purpose, we 
searched the PubMed and Medline databases for articles published in English, Spanish 
and French up to July 31, 2017. Our search terms included a combination of the following 
terms “meningococcal disease”, “bacterial infection”, “sepsis”, “septic shock”, 
“children”, “severe focal infection”, “paediatric intensive care”, “microorganism” and 
“diagnosis”.  
We found that information on the global epidemiology of severe infections in the 
paediatric population is scarce and most published studies on sepsis and severe focal 
infection are biased towards the paediatric intensive care population (Schlapbach LJ et al. 
and Weiss et al). 
 
Added value of this study 
Our study highlights the burden of severe childhood infections, drawing on detailed 
clinical information from the largest prospective cohort of children with severe infection 
in Europe published to date. We demonstrate the continued impact of severe bacterial 
infection and mortality caused by vaccine-preventable infections (N. meningitidis and S. 
pneumoniae), and by pathogens for which vaccines are urgently required (S. aureus and 
Group A streptococcus).  
 
Implications of all the available evidence 
Data collection was made possible by a diverse and widely representative EU funded 
European network (EUCLIDS Project GA: 279185): 194 hospitals in 9 European 
countries, with information on 98 hospitals of 6 of these countries included in this report. 
Conclusions from our data are likely to reflect generalised patterns of illness and to be 
widely relevant across Europe. Our findings emphasize the current burden of infection 
and the need for on going studies of the prevalence and characteristics of serious 
infections in childhood, to guide priorization of therapeutic, diagnostic and preventive 
measures. 
 
This project has received funding from the European Union’s seventh Framework 
program under EC-GA no. 279185 (EUCLIDS). 
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Abstract 
Background: Sepsis and severe focal infections (SFI) represent a significant burden of 
disease in hospitalized children. To understand the burden of disease and outcome of 
childhood infection in Europe, children with life-threatening bacterial infections were 
studied in a multi-centre study in six countries in Europe. 
Methods: Children aged 1 month-to-18 years old with sepsis or SFI, admitted to 98 
European EUCLIDS network hospitals were prospectively recruited during July 2012-
December 2016. Demographic, clinical, microbiological data and outcomes were 
collected.  
Findings: A total of 2,844 patients were included (53.2% male; median age: 39.1 months). 
43.2% of patients (n=1229) had sepsis and 56.8% (n=1615) SFI. Sepsis was diagnosed 
predominantly in younger children and SFI in older ones (P-value<0.0001). Main SFI 
were pneumonia (n=511, 18%), central nervous system infection (n=469, 16.5%) and 
skin and soft tissue infection (n=247, 8.7%). Causal microorganism was identified in 
47.8% of children (n=1,359). Most prevalent causative agent was Neisseria meningitidis 
(9.1%, n=259) followed by Staphylococcus aureus (7.8%, n=222), Streptococcus 
pneumoniae (7.7%, n=219) and Group A streptococcus (5.7%, n=162). Mortality rate was 
2.2% (n=57); and 37.6% of patients (n=1,070) required intensive care.  
Interpretation: Mortality rate in European children hospitalised due to sepsis or SFI is 
low. Burden of disease lies predominantly in children under 5 years and is largely due to 
vaccine-preventable infections by meningococcus and pneumococcus. More than a third 
of children required intensive care. Despite availability and application of current clinical 
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methods for microbiological diagnosis, the causative organism remained unidentified in 
approximately 50% of the patients. 
This project has received funding from the European Union’s seventh Framework 
program under EC-GA no. 279185 (EUCLIDS). 
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Introduction 
The Confidential Enquiry into Maternal and Child Health (CEMACH) report ‘Why 
Children Die’ demonstrated that infectious illness was ‘the single largest cause of death 
in children dying of an acute physical illness’, constituting ‘20% of the deaths overall’ 
with the 1-4 year old group the most affected [1]. Amongst all the infectious agents, 
bacteria represent the principal cause of death in young children, accounting for over a 
third of all child deaths globally [2]. 
The World Health Organization (WHO) recently issued a resolution on sepsis in all age 
groups, recognizing deaths by severe infection as a main target for global and national 
prioritization in healthcare delivery [3]. This burden on childhood morbidity and 
mortality persists despite of the substantial reduction in vaccine-preventable invasive 
bacterial infections after the introduction of conjugate vaccines in childhood and the 
availability of antimicrobial agents [4-6], highlighting the need for a better understanding 
of the host response to infection, novel treatments of acute infection, new methods to 
identify those at risk, and better preventative strategies.  
Currently, information regarding the global epidemiology of severe infections in the 
paediatric population is scarce. Most published studies on sepsis and severe focal 
infection (SFI) are biased towards a predominantly paediatric intensive care unit (PICU) 
population. Reported mortality and morbidity from recent large paediatric sepsis and 
septic shock studies ranged from 17% to 25% [7, 8]. 
In this paper, we present data from the European Union Childhood Life-threatening 
Infectious Disease Study (EUCLIDS), which aimed to describe the current burden of 
severe paediatric infectious diseases, with respect to demographic, clinical, 
microbiological data and outcomes, across Europe. 
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Materials and methods 
Study design and recruitment criteria 
This prospective, multicenter, observational study of children with life-threatening 
bacterial infection presenting to hospital was conducted between July 2012-December 
2016 by the EUCLIDS Consortium (http://www.euclids-project.eu/). This network 
included 194 hospitals in Europe (in 9 countries) and one hospital in Africa (The Gambia). 
Data from Switzerland were not included in the analysis because they used different 
inclusion criteria. The African partner was also excluded because the present study 
focuses on the European burden of disease. 
Eligible participants were children from 1 month to 18 years of age admitted to hospital 
with sepsis (or suspected sepsis) and/or severe focal infection including but not limited 
to pneumonia, soft tissue infection, meningitis, encephalitis, osteomyelitis, and septic 
arthritis (Appendix: Full definitions document, page 43). In order to enrol children as 
early as possible during the infection, potential recruits were identified from their clinical 
characteristics on presentation often before the results from confirmatory microbiology 
tests were available. Additionally, children admitted with proven infections due to N. 
meningitidis, S. pneumoniae, S. aureus and Group A streptococcus (GAS) who had not 
been included in the study on initial presentation to hospital were specifically targeted for 
recruitment. For this reason our findings cannot be used to accurately establish the relative 
prevalence of other potentially causative pathogens. although recruitment mostly took 
place before any causal pathogen was identified. Patients with hospital-acquired 
infections were not included.  
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The study used harmonised procedures for patient recruitment, sample processing and 
sample storage. A common clinical protocol agreed by EUCLIDS Clinical Network and 
approved by the Ethics Comitte was implemented at all hospitals. All clinical staff were 
trained in the projects proceedures, and specified criteria were used for clinical definitions 
and assignment of patients to diagnostic categories. Written informed consent was 
obtained from a parent or legal guardian for each subject before study inclusion.  
Among 7,276 eligible patients included in the EUCLIDS database, we excluded 2,012 
patients labelled as controls, 706 patients recruited retrospecively, 1,479 patients from 
the Swiss and Gambian Cohorts, and 235 that did not meet eligibility criteria or were 
incomplete (Figure 1). Analysis was limited to the remaining 2,844 subjects with a 
complete minimal dataset including patient age and discharge diagnosis. 
Clinical data collection 
The clinical information for each patient was collected using a secured web-based 
platform, including data on demographics, comorbidity, immunisation status, selected 
laboratory results, and past medical and family history of severe infectious diseases 
defined as: (a) any infection requiring hospitalization, if outpatient at onset; (b) any 
infection requiring oxygen, pressors or fluids to support blood pressure, or intubation; or 
(c) deep tissue (invasive) infection requiring intravenous or oral antibiotics to treat 
infection. Discharge diagnosis, clinical course, treatments and specific procedures during 
admission and outcomes (such as death or sequelae) were recorded. 
Patients were categorised into two main groups according to the clinical characteristics 
during the hospital admission: sepsis or SFI. Sepsis was defined as suspected or 
confirmed infection (infectious organisms or toxins) plus systemic inflammatory 
response syndrome (SIRS) [9], and SFI included those illnesses with a suspected or 
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confirmed infection but without SIRS. Patients were assigned one or more pre-defined 
clinical syndromes. (Appendix: Full definitions document, page 43). 
Laboratory methods 
Microbiological diagnosis was undertaken as part of clinical care using locally available 
clinical diagnostic procedures, including, as appropriate, bacterial culture from normally 
sterile sites (blood, cerebrospinal fluid, urine and invasive diagnostic samples), and from 
non-sterile sites (throat and wound swabs); bacterial and viral molecular diagnostics were 
applied to blood, cerebrospinal fluid and respiratory secretions, according to local 
availability.  
In order to assign microbiological aetiology of infection in prospective patients recruited 
to the study, each patient was phenotyped according to their likelihood of bacterial 
infection, using an agreed algorithm, when all the results of investigations were available 
(Figure 2).  
Specific inflammatory parameters: maximum levels of serum C-reactive protein (CRP) 
and neutrophil counts were compared to further assess their utility and sensitivity in 
discriminating focal vs. sepsis, PICU vs. non-PICU admission, and prognosis (survivors 
vs. death). For CRP values, all cohort values were used; while for neutrophil counts only 
UK values were available. Sensitivity and specificity was assessed using pre-agreed cut 
offs and numeric values were used to obtain receiver operating characteristic curves 
(ROC) Figure 2 [10]. 
Statistical analysis 
General data are presented as percentages and odds ratios (OR) computed from 
contigency tables, and medians and interquartile ranges (IQR). Analysis was performed 
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using R version 3.3.1 (www.r-project.org). The level of statistical significance was set at 
0.05. Bonferroni correction was used in order to reduce the likelihood of false positive 
results caused by multiple testing. Associations were assessed using non-parametric tests: 
Fisher’s exact test for discrete variables and Wilcoxon test for continuous variables 
(package stats). ROC curves and areas under curve (AUC) were calculated with P-values 
to test the null hypothesis that the AUC equals 0.50 (package pROC). 
Role of the funding source 
This project has received funding from the European Union’s seventh Framework 
program under EC-GA no.279185 (EUCLIDS). The sponsor of the study had no role in 
study design, data collection, data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
 
Results 
Characteristics of the EUCLIDS cohort 
A total of 2,844 subjects were analysed. 53.2% (1512/2841) were male and the median 
age was 39.1 months (IQR=12.4-93.9). Characteristics of the patients are summarised in 
Table 1.  
A history of previous severe infection was found in 432 (16.9%) cases, whilst 240 cases 
had 1st or 2nd order family members with a history of serious infection (11.0%, 240/2174). 
Previous infections included meningitis (32.9%, 79/240), pneumonia (20.4%, 49/240), 
severe sepsis (11.3%, 27/240) and meningococcemia (7.5%, 18/240). 2.4% of cases 
(51/2127) had parental consanguinity and 2.1% (45/2150) had first- or second-degree 
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relatives with an immunodeficiency. Prematurity was present in 9.8% (230/2343) of the 
cases. 30.1% (497/1652) of the patients lived with smokers at home (Table 1). 
Immunisations were up-to-date according to the local schedules in 93.0% (2240/2409) of 
the patients. Nevertheless, we found that 89.5% (204/228) of the meningococcus isolated 
and serotyped could be eventually covered by vaccines that were not available or not 
included in the immunization calendars implemented in Europe at that time.  
Sepsis was diagnosed predominantly in younger children and SFI in older ones (Figure 
3A), with significant statistical differences in the age distribution between those in whom 
a causative organism was identified and those with no organism identified (Figure 3B, 
Table 1).  
Most of patients (93.4%, 2282/2444) had a favourable clinical course (no death, skin 
grafts, amputations, hearing loss >40dB) with complete recovery from the illness. The 
mortality rate was 2.2% (57/2569) in the entire cohort, 0.5% (7/1549) in SFI vs. 4.9% 
(50/1020) for sepsis. The cause of death for patients included in the SFI sub-cohort is 
specified in Appendix: Cause of death for patients with SFI, page 63.  
A total of 37.6% (1070/2844) patients were admitted to PICU of which 62.1% (763/1229) 
admissions presented with sepsis. 
Microbiological and clinical diagnosis 
A total of 44.8% of children (1155/2581) had definite bacterial infection; 5.9% 
(152/2581) had definite viral; and 47.9% (1202/2509) suffered from uncertain type of 
infection (454 probable bacterial, 65 probable viral and 683 unknown) (Figure 2). 
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A causative microorganism was identified in 47.8% (1359/2844) of the cases. The most 
prevalent bacterial causative agent was Neisseria meningitidis in 9.1% (259/2844) 
followed by Staphylococcus aureus (7.8%, 222/2844), Streptococcus pneumoniae (7.7%, 
219/2844) and GAS (5.7%, 162/2844) (Figure 4). Viruses were identified as causative 
agents in 6.5% (185/2844) of the patients with the most common ones being: enterovirus, 
rhinovirus and respiratory syncytial virus.  
In patients admitted to PICU, the main identified bacteria were: N. meningitidis (16.5%, 
162/981), S. pneumoniae, (9.9%, 97/981), GAS (8.1%, 79/981) and S. aureus (5.5%, 
54/981). Viruses were the causative pathogen in the 8.1% (79/981) of the cases, and there 
was no organism identified in 41.6% (408/981) of the patients. Ward and PICU clinical 
syndromes, and causal agents are shown in Appendix Figure 1, page 64.  
Significant differences were found in N. meningitidis rates in patients with a family 
history of severe bacterial infection [OR: 2.02 (95%CI: 1.31-3.04), P-value=0.0011], and 
in patients exposed to tobacco [OR: 3.21 (95%CI: 2.19-4.74), P-value<0.0001]. In 
premature patients there is a significant difference for viral infection rates [OR: 2.13 
(95%CI: 1.38-3.22), P-value=0.0005].  
Those patients in whom a causative organism was identified were more likely to have 
severe disease: a higher proportion was admitted to PICU (P-value<0.0001) and had a 
prolonged hospital length of stay (LOS) (P-value<0.0001), furthermore, they required 
more respiratory support (P-value<0.0001), and supplemental oxygen (P-value<0.0001). 
Additionally, inotropes (P-value=0.0122) and mortality were higher in patients with an 
identified causative organism (P-value=0.0045) although this was not statistically 
significant after Bonferroni adjustment (Table 1A).  
 12 
Among patients with bacterial SFI, the most prevalent clinical syndromes were 
pneumonia (20.4%, 329/1615), central nervous system (CNS) infection (12.1%, 
196/1615), skin and soft tissue infection (11.5%, 185/1615) and osteomyelitis (9.6%, 
155/1615). 
No correlation was found between administration of antimicrobial agents before cultures 
and organism identification (P-value=0.7813). 
Children whose immunisations were not up to date (7.0%, 169/2409) were admitted 
mainly due to pneumonia (18.9%, 32/169), CNS infections (15.4%, 26/169) and urinary 
tract infections–pyelonephritis (11.8%, 20/169); with S. pneumoniae and Escherichia coli 
being the main causative microorganisms (6.5%, 11/169; and 5.9%, 10/169, respectively).  
We further analysed the main presenting clinical syndromes according to the presence of 
a microorganism. For the main pathologies studied we found that CNS infections were 
caused mainly by N. meningitidis (29.9%, 140/469) and S. pneumoniae (19.0%, 89/469); 
soft tissue infection, osteomyelitis, toxic shock syndrome and septic arthritis by S. aureus 
and GAS, and abdominal conditions and urinary tract infections-pyelonephritis by E. coli. 
(Figure 4A)  
Infection with N. meningitidis (22.8%, 13/57) was the most prevalent among the fatal 
cases, mainly associated with severe sepsis, followed by S. pneumoniae (19.3%, 11/57) 
and S. aureus (10.5%, 6/57). In 33.3% (19/57) of the non-survivors no causative pathogen 
was identified (Figure 4B). 
Sepsis vs. SFI  
The main differences observed between patients with sepsis or SFI were that septic 
patients had a more severe course, with significant differences for all parameters 
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including full recovery at discharge (P-value<0.0001), need for supplemental oxygen (P-
value<0.0001), respiratory support requirement (P-value<0.0001), inotropes (P-
value<0.0001), PICU admission (P-value<0.0091) and death outcome (P-value<0.0001) 
(Table 1B). 
Antibiotics had been administrated before blood cultures were taken in 40.0% (355/887) 
of septic patients and in 29.8% (359/1204) patients with SFI (P-value<0.0001). 
Utility of inflammatory markers 
We compared maximum CRP and neutrophil counts levels between different groups 
(Table 2). Patients with sepsis and those requiring intensive care, had an increased serum 
CRP (≥60 mg/L) compared to those with focal infection and non-PICU admission (P-
value<0.0001). (Appendix Figure 2, page 65). No differences were found when 
comparing survivors vs. non-survivors.  
ROC analysis for CRP to discriminate sepsis vs. SFI showed an AUC of 0.655 (95%CI 
0.616-0.694, P-value<0.0001) and 0.661 (95%CI 0.621-0.701, P-value<0.0001) for 
distinguishing between PICU vs. non-PICU admission. The CRP AUC for discriminating 
between survivors and death was also significant (0.655, 95%CI 0.535-0.776, P-
value=0.0153) (Appendix Figure 3, page 66). 
ROC analysis for neutrophil count to discriminate sepsis vs. SFI showed an AUC of 0.553 
(95%CI 0.523-0.583, P-value<0.0001) and 0.550 (95%CI 0.518-0.582, P-value=0.0015) 
for discriminating between PICU vs. non-PICU admission. The neutrophil AUC for 
discriminating between survivors and death was not significant (0.522, 95%CI 0.390-
0.655, P-value=0.7158) (Appendix Figure 3, page 66).  
Discussion 
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Our study highlights the burden of severe childhood infections, drawing on detailed 
clinical information from the largest prospective cohort of children with severe infection 
in Europe, recruited at 98 hospitals in 6 European countries. We demonstrate the 
continued importance of severe illness and mortality caused by vaccine-preventable 
infections (N. meningitidis and S. pneumoniae), and by pathogens for which vaccines are 
urgently required (S. aureus and GAS).  
Laboratory tests failed to identify a causative pathogen in over half of children with severe 
illness, in line with data from the previous two decades [8, 11], despite the introduction 
of more sensitive and precise techniques in diagnostics in recent years. In over 50% of 
paediatric patients admitted with suspected life-threatening infections, decisions on need, 
type and duration of antimicrobial therapy thus have to be made with no clear guidance 
from the microbiological findings, indicating an urgent need for improved diagnostics. 
Patients with an identified microorganism suffered from more severe disease, which may 
suggest a higher pathogen load and more successful detection in these patients, but may 
be associated as well to increased diagnostic effort in the sickest patients.  
Mortality 
In our study, the case fatality ratio was 2.2%, significantly lower than that recently 
reported by two recent large studies [7, 8], although it should be noted that these studies 
were restricted to PICU patients with a more severe population (sepsis/septic shock). 
Mortality was highest in children with sepsis as defined by the International Paediatric 
Sepsis consensus conference [9]. The new sepsis definitions from 2016 [12] were not 
established for children, hence were not used in our study. Delay in timely treatment has 
been considered to increase the mortality risk in sepsis [6, 13]. Esteban et al. [14] reported 
a trend towards reduction in mortality after implementing an educational intervention for 
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appropriate empiric antibiotic administration within the first hour of admission in children 
with sepsis. However, we were not able to assess this in our data. Our results are 
consistent with the reported mortality rates of patients with sepsis after the introduction 
of adequate treatment guidelines (hospital mortality 1%–3% in previously healthy, and 
7%–10% in chronically ill children) [15], and with a recent population-based study on 
blood culture-proven bacterial sepsis [16]. As previously described [15], we found that 
mortality in community-acquired severe infections [6] was associated with the 
identification of the causative organism, the presence of sepsis, higher PICU admission 
rates, oxygen and/or respiratory support requirement, inotrope administration and 
prolonged LOS.  
Severity and pathogen type 
Though our study was not designed to reliably establish the relative prevalence of 
potentially causative pathogens; our results show the relative frequency of N. meningitidis, 
S. pneumoniae, S. aureus and GAS are roughly equal. Overall, the most frequent clinical 
syndromes were meningitis and pneumonia. Almost half of the patients admitted to 
hospital with a bacterial infection required intensive care admission. These findings are 
consistent with the reported leading causes of morbidity and mortality in children 
worldwide [1, 2]. The causative pathogens in our study differed from findings in Asia: 
were Salmonella enterica serotype Typhi was the most common bacterial pathogen, 
followed by S. pneumoniae and Haemophilus influenzae [17] and Africa: were S. 
pneumoniae is the most common isolate in children, followed by S.aureus and E. coli 
[18]. We also observed differences form studies in the United States were S. aureus, 
Pseudomonas species and Enterobacteriacae (mainly E.coli) were the main pathogens 
isolated. [19]  
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Vaccinations are an essential tool in our fight against infectious disease [4, 20, 21], and 
they have greatly reduced the global burden of infectious disease [21]. Although most 
patients were up-to-date according to their local immunisation schedule, we found that 
there was a considerable burden of mortality and morbidity caused by vaccine preventable 
infections, particularly meningococcal and pneumococcal disease. Vaccines for 
meningococcal serogroup B, Y, W and for a major proportion of pneumococcal serotypes 
are not available or implemented in Europe. Thus, improved vaccines and implementation 
of current vaccines may yield further health gain. Wider implementation of existing 
vaccines and development of vaccines for S. aureus or GAS could contribute to a further 
decline in the burden of paediatric infectious diseases.  
Tobacco smoke exposure 
We found an increased risk of meningococcal infections in children exposed to tobacco 
(P-value<0.0001). In previous studies tobacco smoke exposure was associated with 
increased susceptibility to infections including tuberculosis, pneumonia, meningitis or 
otitis media. This could be explained by increased nasopharyngeal colonization with 
pathogens including S. pneumoniae, H. influenzae (non-type b), M. catarrhalis, GAS and 
S. aureus [22]. Furthermore, increased infection risk can also be explained by the reported 
interference of tobacco smoke with the antibacterial function of leukocytes (e.g. 
neutrophils, monocytes, T cells and B cells) [23]. 
Family history 
The huge variation in clinical response to identical infecting pathogens is most likely the 
result of the combined effects of genetic variation in both the infecting pathogen and the 
infected host [24]. There is now strong evidence that host genetic factors influence 
occurrence of meningococcal disease, and a number of genes controlling susceptibility 
 17 
and severity of meningococcal disease have been identified in candidate gene association 
studies [25-28]. We found a significant association between family history of severe 
infectious diseases and meningococcal infection (P-value=0.0011),  
Inflammatory biomarkers 
In our study, higher CRP levels were associated with an increased risk of severe outcomes. 
Biomarkers may contribute to outcome prediction in life threatening infections [29]. 
However, there is still a need for improved host biomarker and pathogen diagnostics that 
can establish the clinical diagnosis, direct appropriate therapy and enable prediction of 
outcome [10]. Improved diagnostic discrimination in this group could have major 
implications for tackling rising antimicrobial resistance. 
Sepsis outcomes for children in high-income countries have not changed dramatically 
over the past decade [6-8, 13]. Additional diagnostic approaches may help to establish 
the clinical diagnosis, direct early and adequate therapy and enable a more reliable 
outcome prognosis. It has been proposed that an approach combining sensitive pathogen 
diagnostics and novel host response biomarkers may improve treatment and clinical 
outcomes for children with serious infection [10] 
PIRO concept 
We identified specific variables associated with each of the components of PIRO concept 
[30] (predisposition, infection characteristics, host response and organ dysfunction): 
including age, gender, family history of severe infection, tabacco exposure, type of 
microorganism, infection focus, inflammatory biomarkers and a dynamic view of the 
patient’s clinical course and outcomes. All of these variables described, contribute as a 
 18 
proof of concept of this novel approach and as a predictor of mortality for patients with 
community-acquired sepsis. 
Limitations 
Although children were recruited early in their clinical course, before a pathogen 
diagnosis was known, a limitation of our study is that children with known infection due 
to N. meningitidis, S. pneumoniae, S. aureus, and GAS were targeted for recruitment. The 
reason behind this targeted recruitment was to study the genetic basis of these pathogens 
as one of the main objectives of EUCLIDS Project (GA 279185). Overall the majority of 
patients were recruited unbiased, providing a cross section of different etiologies in 
children presenting with severe infection. But specific targeting of the four core 
pathogens will have caused bias towards these infections. The burden of disease from 
these selectively-target pathogens is within this study cohort but our study design limits 
the ability to generalize this to the broader population. Our findings thus cannot be used 
to establish population prevalence of each organism. Of note, one of EUCLIDS centres 
(Switzerland), where the recruitment strategy was to enroll children at a later time point, 
solely after confirmation of positive blood culture, were not included in this paper. In 
order to determine the disease burden and to elucidate the contributing factors to severe 
infection outcome, large epidemiological studies are needed. Recruitment was restricted 
to the hospital setting and did not capture out-of-hospital deaths, or severe focal infections 
managed as outpatients; our data therefore under-represent less severe infections. 
Eventhough the study used harmonised procedures for patient recruitment, sample 
processing, and sample storage, microbiological diagnosis was undertaken as part of 
clinical care using locally available clinical diagnostic procedures which could have 
limited in some way the assignment of patients as having viral infection, bacterial 
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infection or co infection. We will report separately on additional viral studies undertaken 
as part of EUCLIDS using molecular diagnosis for a wide range of viruses. 
Conclusions 
This is the largest reported prospective study of severe childhood infections in Europe. 
Data collection was made possible by a diverse and widely representative European 
network. Recommendations or interventions based on our data are likely to reflect 
generalised patterns of illness and to be widely relevant across Europe. Although the 
mortality rate due to sepsis or SFI was low, we found considerable morbidity associated 
with severe childhood infection and more than a third of children required PICU 
admission. The burden of disease lies predominantly in children under 5 years and was 
predominantly caused by infections where vaccines are available: pneumococcus and 
meningococcus. We found that children had infections by common pathogens such as S. 
aureus (7.8%) and GAS (5.7%) for which there are no effective vaccines, and that 11.0% 
of the bacterial microorganisms were Gram-negative bacilli. Both of which, should have 
important implications for vaccine development and for empirical antimicrobial strategies 
implementation in Europe. 
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Table 1: Description of the main characteristics of the EUCLIDS study cohort. 
Comparision between (A) no organism and organism identified, and (B) focal infection 
and sepsis. Data are expressed as % (n) or median (IQR). * P-values lower than 
Bonferroni correction threshold (0.05/37=0.0014). 
A) 
Variables All patients No organism 
identified 
Organism 
identified 
P-value 
Total cohort 2844 52.2% (1485/2484) 47.8% (1359/2844)  
Demographic characteristics 
Sex (male) 53.2% (1512/2841) 53.9% (800/1484) 52.5% (712/1357) 0.4517 
Age 39.1 (12.4-93.9) 42.8 (14.9-95.5) 33.2 (10.25-91.05) 0.0007* 
0-12 months 24.3% (691/2844) 21.1% (313/1485) 27.8% (378/1359) 0.0005* 
12-24 months 14.8% (421/2844) 14.5% (215/1485) 15.2% (206/1359) – 
24-48 months 17.1% (487/2844) 18.3% (272/1485) 15.8% (215/1359) – 
>48 months 43.8% (1245/2844) 46.1% (685/1485) 41.2% (560/1359) – 
Weight (kg) 14.8 (9.9-25.8) 15.4 (10.3-26.5) 14.0 (9.2-25.5) 0.0005* 
Family history 
Severe infections 11.0% (240/2174) 10.1% (115/1143) 12.1% (125/1031) 0.1319 
Immunodeficiency 2.1% (45/2150) 2.1% (24/1133) 2.1% (21/1017) 1.0000 
Consanguinity 2.4% (51/2127) 2.6% (29/1122) 2.2% (22/1005) 0.5734 
Smoker in the household 30.1% (497/1652) 28.3% (250/883) 32.1% (247/769) 0.0957 
Patient medical history 
Premature birth 9.8% (230/2343) 9.9% (123/1244) 9.7% (107/1099) 0.9446 
Past severe infections 16.9% (432/2563) 18.9% (252/1336) 14.7% (180/1227) 0.0051 
Immunisations up-to-date 93.0% (2240/2409) 93.5% (1194/1277) 92.4% (1046/1132) 0.2998 
Clinical data 
Antibiotics before culture 34.1% (714/2091) 34.4% (393/1142) 33.8% (321/949) 0.7813 
PRISM Score 11 (5-20) 10.5 (4-16) 12.0 (5.0-21) 0.1097 
Full recovery expected 93.4% (2282/2444) 95.7% (1219/1274) 90.9% (1063/1170) <0.0001* 
PICU admission 37.6% (1070/2844) 30.0% (445/1485) 46.0% (625/1359) <0.0001* 
Oxygen needed 36.3% (923/2546) 32.0% (426/1333) 41.0% (497/1213) <0.0001* 
Respiratory support 28.1% (720/2564) 23.3% (313/1345) 33.4% (407/1219) <0.001* 
Inotropes 11.8% (304/2578) 10.3% (138/1346) 13.5% (166/1232) 0.0122 
Hospital LOS 7 (4-13) 6 (3-10) 10 (6-16) <0.0001* 
Death 2.2% (57/2569) 1.4% (19/1345) 3.1% (38/1224) 0.0045 
Clinical syndrome     
CLABSI 0.5% (13/2844) 0.1% (2/1485) 0.8% (11/1359) 0.0099 
CNS infection 16.5% (469/2844) 8.8% (130/1485) 24.9% (339/1359) <0.0001* 
Bronchiolitis 2.7% (78/2844) 2.1% (31/1485) 3.5% (47/1359) 0.0287 
Pneumonia 18.0% (511/2844) 22.5% (334/1485) 13.0% (177/1359) <0.0001* 
LRTI 3.5% (100/2844) 4.7% (70/1485) 2.2% (30/1359) 0.0003* 
Lung effusion or empyema 7.4% (210/2844) 6.3% (94/1485) 8.5% (116/1359) 0.0261 
Soft tissue infection 8.7% (247/2844) 9.2% (136/1485) 8.2% (111/1359) 0.3518 
Toxic shock syndrome 2.3% (64/2844) 1.1% (16/1485) 3.5% (48/1359) <0.0001* 
Endocarditis 0.7% (20/2844) 0.1% (2/1485) 1.3% (18/1359) 0.0001* 
Osteomyelitis 6.7% (191/2844) 5.2% (77/1485) 8.4% (114/1359) 0.0010 
Scarlet fever 0.3% (9/2844) 0.3% (5/1485) 0.3% (4/1359) 1.0000 
Septic arthritis 5.2% (149/2844) 3.4% (50/1485) 7.3% (99/1359) <0.0001* 
Gastroenteritis 1.6% (45/2844) 1.3% (19/1485) 1.9% (26/1359) 0.1800 
UTI–pyelonephritis 3.8% (109/2844) 2.6% (39/1485) 5.2% (70/1359) 0.0006* 
ENT 6.3% (178/2844) 7.8% (116/1485) 4.6% (62/1359) 0.0003* 
Abdominal condition 1.3% (38/2844) 1.5% (22/1485) 1.2% (16/1359) 0.5166 
Severe sepsis 5.5% (157/2844) 3.6% (54/1485) 7.6% (103/1359) <0.0001* 
Septic shock 9.3% (264/2844) 6.2% (92/1485) 12.7% (172/1359) <0.0001* 
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B) 
Variables Focal infection Sepsis  P-value 
Total cohort 56.8% (1615/2844) 43.2% (1229/2844)  
Demographic characteristics 
Sex (male) 53.5% (863/1612) 52.8% (649/1229) 0.7045 
Age 46.5 (15.8-100.4) 27.6 (9.0-80.2) <0.0001* 
0-12 months 19.8% (319/1615) 30.3% (372/1229) 0.0005* 
12-24 months 13.6% (220/1615) 16.4% (201/1229) – 
24-48 months 18.1% (293/1615) 15.8% (194/1229) – 
>48 months 48.5% (783/1615) 37.6% (462/1229) – 
Weight (kg) 15.8 (10.7-28.0) 13.0 (8.7-23.1) <0.0001* 
Family history 
Severe infections 11.2% (137/1220) 10.8% (103/954) 0.7828 
Immunodeficiency 2.1% (25/1211) 2.1% (20/939) 1.0000 
Consanguinity 1.9% (22/1186) 3.1% (29/941) 0.0859 
Smoker in the household 31.7% (301/951) 28% (196/701) 0.1155 
Patient medical history 
Premature birth 8.5% (112/1316) 11.5% (118/1027) 0.0173 
Past severe infections 18.7% (270/1441) 14.4% (162/1122) 0.0041 
Immunisations up-to-date  93.2% (1282/1375) 92.6% (958/1034) 0.5740 
Clinical data 
Antibiotics before culture 29.8% (359/1204) 40% (355/887) <0.0001* 
PRISM Score 5 (4-11.75) 14 (6-22) <0.0001* 
Full recovery expected 97.2% (1369/1409) 88.2% (913/1035) <0.0001* 
PICU admission 19.0% (307/1615) 62.1% (763/1229) <0.0001* 
Oxygen needed 22.1% (323/1463) 55.4% (600/1083) <0.0001* 
Respiratory support 11.8% (172/1454) 49.4% (548/1110) <0.0001* 
Inotropes 10.3% (151/1472) 44.4% (498/1121) <0.0001* 
Hospital LOS 6 (3-12) 9 (5-15) <0.0001* 
Death 0.5% (7/1549) 4.9% (50/1020) <0.0001* 
Clinical syndrome 
CLABSI 0.1% (1/1615) 1.0% (12/1229) 0.0001* 
CNS infection 12.1% (196/1615) 22.2% (273/1229) <0.0001* 
Bronchiolitis 2.7% (44/1615) 2.8% (34/1229) 1.0000 
Pneumonia 20.4% (329/1615) 14.8% (182/1229) <0.0001* 
LRTI 4.3% (69/1615) 2.5% (31/1229) 0.0134 
Lung effusion or empyema 8.4% (136/1615) 6.0% (74/1229) 0.0168 
Soft tissue infection 11.5% (185/1615) 5.0% (62/1229) <0.0001* 
Toxic shock syndrome 0.3% (5/1615) 4.8% (59/1229) <0.0001* 
Endocarditis 0.2% (4/1615) 1.3% (16/1229) 0.0011 
Osteomyelitis 9.6% (155/1615) 2.9% (36/1229) <0.0001* 
Scarlet fever 0.4% (7/1615) 0.2% (2/1229) 0.3150 
Septic arthritis 7.5% (121/1615) 2.3% (28/1229) <0.0001* 
Gastroenteritis 1.9% (31/1615) 1.1% (14/1229) 0.1285 
UTI–pyelonephritis 4.0% (64/1615) 3.7% (45/1229) 0.6947 
ENT 9.0% (145/1615) 2.7% (33/1229) <0.0001* 
Abdominal condition 1.4% (22/1615) 1.3% (16/1229) 1.0000 
Severe sepsis 0% (0/1615) 12.8% (157/1229) <0.0001* 
Septic shock 0% (0/1615) 21.5% (264/1229) <0.0001* 
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Table 2: Description of serum levels of C-reactive protein (CRP) and neutrophil 
counts in different group of patients. Data are expressed as % (n). * P-values lower 
than Bonferroni correction threshold (0.05/4=0.0125). SFI: Severe focal infection; PICU: 
paediatric intensive care unit. 
 CRP≥60 mg/L CRP<60 mg/L P-value Neutrophilis≥12109/L Neutrophils<12109/L P-value 
Total  39.7 (966/2432) 60.3 (1466/2432)  68.2 (977/1432) 31.8 (455/1432)  
Sepsis vs. focal       
  Sepsis 71.6 (755/1054) 28.4 (299/1054) <0.0001* 35.8 (226/631) 64.2 (405/631) 0.0042* 
  SFI 51.6 (711/1378) 48.4 (667/1378)  28.6 (229/801) 71.4 (572/801)  
PICU vs. not PICU       
  PICU 70.9 (654/922) 29.1 (268/922) <0.0001* 36.3 (190/524) 63.7 (334/524) 0.0067* 
  Non-PICU 53.8 (812/1510) 46.2 (698/1510)  29.2 (265/908) 70.8 (643/908)  
Survivors vs. death       
  Survivors 59.5 (1273/2139) 40.5 (866/2139) 0.0878 32.3 (397/1230) 67.7 (833/1230) 0.5039 
  Death 72.7 (32/44) 27.3 (12/44)  39.1 (9/23) 60.9 (14/23)  
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Figure 1: Consort Flow Diagram 
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Figure 2: Phenotyping algorithm. Figure adapted from Herberg et al. [10] 
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Figure 3: A) Age distribution in the EUCLIDS cohort and in those diagnosed with 
sepsis or a focal illness. B) Age distribution by causative organism. GPC: gram 
positive cocci, GAS: Group A Streptococcus, GNR: gram negative rods, CoNS: 
Coagulase Negative Staphylococci. 
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Figure 4. Causative microorganisms identified in EUCLIDS by syndrome. (A) 
patients with severe focal infections and (B) sepsis. Data are expressed as (n) %. CNS 
infection: central nervous system infection, LRTI: lower respiratory tract infection, ENT 
syndrome: ear, nose, throat syndrome, UTI-pyelonephritis: urinary tract infection with 
pyelonephritis, GPC: gram positive cocci, GAS: Group A Streptococcus; GNR: gram 
negative rods, CoNS: Coagulase Negative Staphylococci. 
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Appendix: EUCLIDS CONSORTIUM MEMBERS 
EUCLIDS consortium (www.euclids-project.eu) is composed by: 
Imperial College partner (UK) 
Members of the EUCLIDS Consortium at Imperial College London (UK)  
Principal and co-investigators 
Michael Levin (grant application, EUCLIDS Coordinator) 
Dr. Lachlan Coin (bioinformatics) 
Stuart Gormley (clinical coordination) 
Shea Hamilton (proteomics) 
Jethro Herberg (grant application, PI) 
Bernardo Hourmat (project management) 
Clive Hoggart (statistical genomics) 
Myrsini Kaforou (bioinformatics) 
Vanessa Sancho-Shimizu (genetics) 
Victoria Wright (grant application, scientific coordination) 
Consortium members at Imperial College 
Amina Abdulla 
Paul Agapow 
Maeve Bartlett 
Evangelos Bellos 
Hariklia Eleftherohorinou 
Rachel Galassini 
David Inwald 
Meg Mashbat 
Stefanie Menikou 
Sobia Mustafa  
Simon Nadel 
Rahmeen Rahman 
Clare Thakker 
 
EUCLIDS UK Clinical Network 
 
Poole Hospital NHS Foundation Trust, Poole: Dr S Bokhandi (PI), Sue Power, Heather 
Barham 
Cambridge University Hospitals NHS Trust, Cambridge: Dr N Pathan (PI), Jenna Ridout, 
Deborah White, Sarah Thurston 
 
University Hospital Southampton, Southampton: Prof S Faust (PI), Dr S Patel (co-
investigator), Jenni McCorkell. 
 
Nottingham University Hospital NHS Trust: Dr P Davies (PI), Lindsey Crate, Helen 
Navarra, Stephanie Carter 
 
University Hospitals of Leicester NHS Trust, Leicester: Dr R Ramaiah (PI), Rekha Patel 
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Portsmouth Hospitals NHS Trust, London: Dr Catherine Tuffrey (PI), Andrew Gribbin, 
Sharon McCready 
 
Great Ormond Street Hospital, London: Dr Mark Peters (PI), Katie Hardy, Fran Standing, 
Lauren O’Neill, Eugenia Abelake 
 
King’s College Hospital NHS Foundation Trust, London; Dr Akash Deep (PI), Eniola 
Nsirim 
 
Oxford University Hospitals NHS Foundation Trust, Oxford Prof A Pollard (PI), Louise 
Willis, Zoe Young 
 
Kettering General Hospital NHS Foundation Trust, Kettering: Dr C Royad (PI), Sonia 
White 
 
Central Manchester NHS Trust, Manchester: Dr PM Fortune (PI), Phil Hudnott 
 
 
SERGAS Partner (Spain) 
 
Principal Investigators 
Federico Martinón-Torres1 
Antonio Salas1,2 
 
GENVIP RESEARCH GROUP (in alphabetical order): 
Fernando Álvez González1, Ruth Barral-Arca1,2, Miriam Cebey-López1, María José 
Curras-Tuala1,2, Natalia García1, Luisa García Vicente1, Alberto Gómez-Carballa1,2, Jose 
Gómez Rial1, Andrea Grela Beiroa1, Antonio Justicia Grande1, Pilar Leboráns Iglesias1, 
Alba Elena Martínez Santos1, Federico Martinón-Torres1, Nazareth Martinón-Torres1, 
José María Martinón Sánchez1, Beatriz Morillo Gutiérrez1, Belén Mosquera Pérez1, Pablo 
Obando Pacheco1, Jacobo Pardo-Seco1,2, Sara Pischedda1,2, Irene Rivero Calle1, Carmen 
Rodríguez-Tenreiro1, Lorenzo Redondo-Collazo1, Antonio Salas Ellacuriaga1,2, Sonia 
Serén Fernández1, María del Sol Porto Silva1, Ana Vega1,3, Lucía Vilanova Trillo1. 
1 Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital 
Clínico Universitario de Santiago, Santiago de Compostela, Spain, and GENVIP 
Research Group (www.genvip.org), Instituto de Investigación Sanitaria de Santiago, 
Galicia, Spain. 
2 Unidade de Xenética, Departamento de Anatomía Patolóxica e Ciencias Forenses, 
Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de 
Compostela, and GenPop Research Group, Instituto de Investigaciones Sanitarias (IDIS), 
Hospital Clínico Universitario de Santiago, Galicia, Spain 
3 Fundación Pública Galega de Medicina Xenómica, Servizo Galego de Saúde (SERGAS), 
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Appendix: Full definitions document 
1. Focal infections 
1.1. Lung infections 
1.1.1. Pneumonia 
It is an inflammation of one or both lungs: Lobar or segmental or multilobar 
collapse/consolidation on CXR. Do not include perihilar consolidation or patchy 
consolidation. 
Clinical symptoms compatible with acute respiratory infection and following radiological 
findings of consolidation/pleural effusion: alveolar consolidation (defined as a dense or 
fluffy opacity that occupies a portion or whole of a lobe or of the entire lung that may or 
may not contain air-bronchograms) or pleural effusion (defined as fluid in the lateral 
pleural space and not just in the minor or oblique fissure) that was spatially associated 
with a pulmonary parenchymal infiltrate (including other infiltrate) or obliterated enough 
of the hemithorax to obscure an opacity. 
1.1.2. Pleural Effusion / Empyema 
Simple parapneumonic effusion is defined as pleural effusion associated with lung 
infection (ie, pneumonia). These effusions result from the spread of inflammation and 
infection to the pleura. Much less commonly, infections in other adjacent areas (eg, 
retropharyngeal, vertebral, abdominal, and retroperitoneal spaces) may spread to the 
pleura resulting in the development of effusion. 
Empyema is defined as the presence of grossly purulent fluid in the pleural cavity. In 
practice: 
 Thoracentesis with microbial growth from pleural fluid or 
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 Thoracentesis with no growth on culture of pleural fluid but elevated protein, or 
cell count (normal and abnormal reference values as determined by clinical 
laboratory at each center) 
 Ultrasound or other diagnostic imaging evidence of pleural fluid assessed by the 
radiologist as empyema or 
 Diagnosis at time of thoracic surgery. 
1.1.3. Whooping cough (Bordetella pertussis) 
Clinical diagnosis — For endemic or sporadic cases, a clinical case of pertussis is defined 
as an acute cough illness lasting at least 14 days accompanied by one of the following: 
 Paroxysms of coughing  
 Inspiratory whoop 
 Post-tussive vomiting 
In an outbreak or following household contact to a known case, a clinical case is defined 
as a cough illness for at least 14 days; presence of the typical pertussis- associated features 
is not required. 
Definite diagnosis — Clinical diagnosis confirmed by bacterial culture, polymerase chain 
reaction (PCR) or serology. Note that direct fluorescent antibody should not be 
considered due to variable specificity. 
1.1.4. Bronchiolitis 
Bronchiolitis is diagnosed clinically by the presence of viral upper respiratory prodromes 
followed by increased respiratory effort (eg, tachypnea, nasal flaring, chest retractions) 
and wheezing and/or rales in children younger than two years of age. 
1.2. Neurological infections: 
1.2.1. Meningitis 
 44 
Meningitis is an infection of the membranes covering the brain and spinal cord 
(leptomeninges). 
Compatible clinical syndrome: Any child (0-18 years) with clinical symptoms compatible 
with meningitis (a severe headache, fever, nausea, vomiting and feeling generally unwell). 
The symptoms in babies and young children are: becoming floppy and unresponsive, or 
stiff with jerky movements, becoming irritable and not wanting to be held, unusual crying, 
pale and blotchy skin, refusing feeds, loss of appetite, a staring expression, very sleepy 
and reluctant to wake up. 
Definite bacterial meningitis 
Compatible clinical syndrome, plus  
 All ages: fever, 94% 
 1–5 mos: irritability, 85% 
 6–11 mos: impaired consciousness, 79% 
 >12 mos: vomiting, 82%; neck rigidity, 78% 
 (note: many other compatible signs and symptoms) plus 
Positive culture of cerebrospinal fluid (CSF), or positive CSF Gram stain, PCR or 
bacterial antigen. 
Probable bacterial meningitis 
Compatible clinical syndrome, plus  
Positive culture of blood, plus 
One of the following CSF changes 
 >5 leukocytes 
 Protein of >100 mg/dL 
 Glucose of <40mg/dl (<2.2mmol/l) or 0.5 CSF/serum ratio 
Possible bacterial meningitis 
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Compatible clinical syndrome, plus  
 One of the following CSF changes 
o >100 leukocytes 
o Glucose of < 40 mg/dl (<2.2mmol/l) or CSF/serum glucose ratio 0.5  
o Protein of > 100 mg/dL plus 
 Negative cultures or antigen for bacteria, viral, fungal, or mycobacteria 
Confirmed: A case that is laboratory-confirmed by growing (i.e. culturing) or identifying 
(i.e. by PCR or Gram stain or antigen detection methods) a bacterial pathogen (Hib, 
pneumococcus or meningococcus) in the CSF or from the blood in a child with a clinical 
syndrome consistent with bacterial meningitis 
Note: Any persons with H. influenzae, meningococcus or pneumococcus isolated from 
CSF or blood may be considered as confirmed cases of meningitis if their clinical 
syndrome was meningitis (i.e. culture from normally sterile fluids is the gold standard). 
Culture of Hib, pneumococcus or meningococcus from a non-sterile site, such as the 
throat, does not confirm a case of disease, since the bacteria can grow in these other areas 
without causing disease. 
1.2.2. Bacterial brain abscess 
Brain abscess is a focal collection within the brain parenchyma caused by a bacterial 
infection, which can arise as a complication of a variety of infections, trauma, or surgery. 
The diagnosis of focal collection is confirmed by CT scan with contrast or MRI. 
The diagnosis of bacterial brain abscess is confirmed by a positive culture or positive 
Gram stain or positive 16s or bacterial antigen in specimen obtained from stereotactic 
CT-guided aspiration or surgery. 
For EUCLIDS purposes, possible bacterial brain abscess can be included only on clinical 
and radiological findings. 
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1.3. Bone and Joint infection 
1.3.1. Osteomyelitis: 
It is defined as an inflammation or an infection in the bone marrow and surrounding bone.  
In the EUCLIDS study both acute, subacute and chronic bacterial osteomyelitis are of 
interest and to be included: 
 Acute osteomylitis is defined by a duration of symptoms < 14 days. 
 Subacute osteomyelitis is definedy by a duration of symptoms between 14 days 
and 1 month. 
 Chronic osteomyelits is defined by a duration of symptoms more than 1 month. 
The diagnosis of acute/subacute/chronic osteomyelitis is based on the following criteria: 
 Presence of localized pain/tenderness and other typical features of osteomyelitis 
(warmth and/or swelling of the affected region) 
AND/OR  
 Imaging findings conistent with osteomyelitis (typical MRI findings and/or a 
positive bone scan) 
AND/OR 
  Bacteriologic evidence of infection (positive blood and/or bone culture). 
AND/OR 
  Histopathological finding consistent with osteomyelitis (intraoperative 
specimen) 
For diagnosis of osteomyelitis at least two criteria must be positive. 
1.3.2. Septic arthritis: 
It is diagnosed when a microorganism is isolated from blood with clinical arthritis, from 
the synovial fluid and/or purulent fluid is aspirated from the joint. Synovial fluid with 
white blood cell count (WBC) 50,000/mm3 is considered purulent. 
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MRI findings consistent with acute/subacute/chronic osteomyelitis: 
 On unenhanced images, osteomyelitis is characterized by focally decreased 
marrow signal intensity on T1-weighted images AND focally increased marrow 
signal intensity on fluid-sensitive images (fat-suppressed T2-weighted and STIR 
sequences). 
OR 
 After contrast administration, osteomyelitis is described as focal abnormal bone 
marrow enhancement on fat-suppressed T1-weighted images. 
AND/OR 
 Complications of osteomyelitis can include abscesses: Intraosseous, subperiosteal, 
and soft-tissue abscesses are defined as well circumscribed areas of focally 
decreased signal intensity on T1-weighted images with increased signal intensity 
equal to that of fluid on fluid-sensitive sequences and/or rim enhancement on 
contrast-enhanced fat-suppressed T1-weighted images. 
 Subacute osteomyelitis can manifest as Brodie abscess characterized by a central 
abscess cavity filled with fluid, an inner ring of enhancing high signal intensity 
granulation tissue on T1-weighted sequences, an outer ring of very low signal 
intensity sclerosis, and a peripheral halo of edema. 
 In chronic osteomyelitis, imaging might reveal an involucrum (thick periosteal 
new bone), sequestrum (necrotic bone fragment), or cloaca (draining tract through 
a defect in the cortex and involucrum). 
Bone scan consistent with osteomyelitis (Technetium-99m bone scan): 
• The most definitive phase is the delayed phase: There is no osteomyelitis without 
abnormal radionuclide uptake on the images obtained during the delayed phase, 
even if there is increased activity on blood flow or blood pool images. 
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AND/OR 
• The hallmark feature of osteomyelitis at 99mTc scintigraphy is increased activity 
in all three phases (1. angiographic or blood flow phase, 2. blood pool or tissue 
phase and 3. delayed phase). 
Histopathological finding consistent with acute/subacute/chronic osteomyelitis: 
 Inflammatory cells 
o Inacute osteomyelitis: predominately polymorphonuclear leucocytes 
o In chronic osteomyelitis: mononuclear cells including plasma cells and 
macrophage/monocyte cells  
AND/OR 
 Destruction/necrosis of bone (necrotic marrow and bone, osteoclastic activity)  
AND/OR 
 Granulation tissue (hemorrhage, polymorphonuclear leucocytes, lymphocytes, 
and macrophages) 
AND/OR 
 In implant-associated infections, tissue specimens obtained for histopathology 
either by biopsy or during surgery as frozen section are important because the 
presence of neutrophils in significant amounts is indicative of infection. More 
than five neutrophils per high-power field indicates infection, with sensitivity of 
43–84% and specificity of 93–97%. These infections will be considered as 
“community acquired” depending on the onset of symptoms after implantation: if 
>24months have elapsed it is considered a community acquired infection. 
1.3.3. Diskitis/spondilodiskitis 
Diskitis is an inflammatory process involving the intervertebral disks and the endplates 
of the vertebral bodies, and associated with characteristic clinical and radiologic findings. 
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1.3.4. Mastoiditis 
Mastoiditis is a suppurative infection of the mastoid air cells, and the most common 
suppurative complication of acute otitis media. In acute mastoiditis, symptoms are of less 
than 1 month’s duration. 
There is a lack of consensus regarding the criteria and strategies for diagnosing acute 
mastoiditis in the paediatric population. The diagnosis is usually made clinically, without 
need for imaging studies. 
 Clinical features: 
o Fever 
o Otalgia 
o Post-auricular erythema, tenderness, swelling, fluctuance or mass 
o Displacement of the auricle (down and out: children <2years); up and out in 
children ≥2years 
 Imaging: CT, MRI: Haziness or destruction of the mastoid outline; and loss of or 
decrease in the sharpness of the bony septa that define the mastoid air cells. 
 Microbiology: Positive culture or gram stain of a specimen obtained from the 
middle ear either by tympanocentesis through an intact eardrum or by aspiration 
through a tympanostomy tube or perforation. 
1.4. Soft tissue infections: 
1.4.1. Cellulitis 
Acute, diffuse, spreading infection of the skin, involving the deeper layers of the skin and 
the subcutaneous tissue. 
1.4.2. Ecthyma /erysipelas 
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Ecthyma is a bacterial infection of the dermis and epidermis characterized by a vesicle or 
vesico-pustule with an erythematous base that erodes through the epidermis into the 
dermis to form a crusted ulcer with elevated margins up to 4 cm in diameter. 
Clinical diagnosis is confirmed by a positive culture or Gram stain of the lesion. 
Erysipelas is a superficial form of cellulitis with lymphatic involvement. 
1.4.3. Necrotizing fasciitis 
Necrotizing fasciitis is an infection of the deeper tissues that results in rapidly progressive 
destruction of the muscle fascia, overlying subcutaneous fat and epidermis. The definite 
diagnosis is surgical. 
1.4.4. Myositis / pyomyositis 
Myositis is an inflammation of the skeletal muscles, often caused by infection or 
autoimmune disease. Pyomyositis is a bacterial infection of the skeletal muscle that is 
usually caused by Staphylococcus aureus. 
Pyomyositis is suspected by the clinical presentation (fever and pain with 
cramping usually localized to a single muscle group) and compatible findings in image 
techniques (Rx, CT, US, MRI). Definite diagnosis is made by culture and gram stain of 
drainage specimen. 
1.4.5. Deep neck infections 
Suppurative infection of the neck, including: 
•  Peritonsillar abscess: Collection of pus located between the capsule of the palatine 
tonsil and the pharyngeal muscles. 
•  Retropharyngeal abscess: Collection of pus located in the retropharyngeal space 
(extending from the base of the skull to the posterior mediastinum, between the 
middle layer and the deep layer of the deep cervical fascia). 
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•  Lateral pharyngeal space infection: Collection of pus located in the lateral 
pharyngeal space (bounded laterally by the carotid sheath). 
Suppurative cervical lymphadenitis: Enlarged, inflamed and tender lymph node 
with or without fluctuance, usually unilateral. Clinical diagnosis is confirmed by 
positive culture or Gram stain of specimen obtained by needle aspiration or 
incision and drainage. 
1.5. Intra-abdominal infections:  
1.5.1. Acute appendicitis 
Acute inflammation of the appendix, usually resulting from bacterial infection. 
Clinical presentation is variable, often consisting of abdominal pain and tenderness in 
periumbilical region (early) migrating to the right lower quadrant of the abdomen, 
vomiting, fever and signs of localized or generalized peritoneal irritation. 
Definite diagnosis is made by demonstration of an inflamed or perforated appendix on 
pathology after surgical removal. 
1.5.2. Infectious peritonitis 
Infection of the peritoneum, usually secondary to inoculation of the peritoneal cavity with 
bacteria and other inflammatory debris following intestinal perforation or postoperative 
anastomotic leak. Acute appendicitis is the most commonly associated condition leading 
to secondary peritonitis in older children. 
Clinical diagnosis is confirmed by positive culture or Gram stain of peritoneal fluid. 
1.5.3. Pyelonephritis 
Urinary tract infection affecting the renal parenchyma and pelvis. In a patient with fever 
in absence of another source of infection: 
• Possible pyelonephritis: presence of positive leukocyte esterase test results or 
nitrite test or microscopic analysis results positive for leukocytes or bacteria in a 
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urine specimen collected by the most convenient means and compatible findings in 
renal ultrasonography, voiding cystourethrography or nuclear scanning with 
technetium- labeled dimercaptosuccinic acid. 
• Definite pyelonephritis: 
o Presence of both pyuria and at least 50,000 colonies per mL of a single 
uropathogenic organism in an appropriately collected specimen of urine (by 
urethral catheterization or suprapubic aspiration) 
o and compatible findings in renal ultrasonography, voiding cystourethrography 
or nuclear scanning with technetium-labeled dimercaptosuccinic acid. 
2. Toxic shock definition: 
2.1. Staphylococcal toxic shock syndrome clinical case definition 
1. Fever ≥38,9°C 
2. Rash—diffuse macular erythroderma 
3. Desquamation—1–2 weeks after onset of illness, especially of palms and soles  
4. Hypotension—systolic blood pressure ≤90 mm Hg for adults 
5. Multi-system involvement—3 or more of the following: 
a) Gastrointestinal—vomiting or diarrhoea at the onset of illness 
b) Muscular—severe myalgia or elevated creatine phosphokinase 
c) Mucous membranes—vaginal, oropharyngeal, conjunctival hyperaemia 
d) Renal—blood urea nitrogen or creatinine twice-upper limit of normal 
e) Hepatic—total bilirubin twice-upper limit of normal 
f) Haematological—platelets ≤100×109/L 
g) CNS—disorientation or alterations in consciousness without focal neurological 
signs 
6. Negative results on the following tests: 
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a) Blood, throat, or cerebrospinal fluid culture for another pathogen (blood culture 
may be positive for Staphylococcus aureus) 
b) Rise in titre to Rocky Mountain spotted fever, leptospirosis, or measles 
Case classification: 
- Probable: case with five of the six clinical findings described  
- Confirmed: case with all six of the clinical findings described 
2.2. Streptococcal toxic shock syndrome clinical case definition 
1. Isolation of group A β-haemolytic streptococci:  
a) From a normally sterile site—blood, CSF, peritoneal fluid, tissue biopsy 
b) From a non-sterile site—throat, vagina, sputum 2. Clinical signs of severity: 
a) Hypotension—systolic blood pressure ≤90 mm Hg in adults or below normal age 
adjusted levels in children 
b) Two or more of the following signs: 
i) Renal impairment—creatinine >2 mg/dL (>177 μmol/L) 
ii) Coagulopathy—platelets ≤100×109/L or disseminated intravascular coagulation  
iii) Hepatic involvement—alanine aminotransferase, aspartate aminotransferase, or 
total bilirubin twice the upper limit of normal 
iv) Adult respiratory distress syndrome 
v) Generalised, erythematous, macular rash that may desquamate 
vi) Soft-tissue necrosis, including necrotising fasciitis, myositis, or gangrene 
Case classification: 
 Probable: case fulfils 1b and 2 (a and b) if no other cause for the illness is found – 
 Confirmed: case fulfils 1a and 2 (a and b) 
3. Clinical syndromes 
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3.1. Bacteraemia/septicaemia: 
3.1.1. Systemic Inflammatory Response Syndrome (SIRS) 
As per clinical criteria established by Goldstein et al, SIRS is defined by at least two of 
the following four criteria: 
1.- Core (rectal, bladder, oral or central catether probe) temperature of > 38.5oC or < 
36oC. 
2.- Tachycardia, defined as a mean heart rate >2 SD above normal for age in the 
absence of external stimulus, chronic drugs, or painful stimuli; or otherwise 
unexplained persistent elevation over a 0.5- to 4-hr time period or OR for children 
<1 yr old: bradycardia, defined as a mean heart rate <10th percentile for age in the 
absence of external vagal stimulus, B-blocker drugs, or congenital heart disease; or 
otherwise unexplained persistent depression over a 0.5-hr time period. 
3.- Mean respiratory rate >2 SD above normal for age or mechanical ventilation for 
an acute process not related to underlying neuromuscular disease or the receipt of 
general anesthesia. 
4.- Leukocyte count elevated or depressed for age (not secondary to chemotherapy- 
induced leukopenia) or > 10% immature neutrophils. 
3.1.2. Sepsis 
Defined as suspected infection plus SIRS, as per clinical criteria established by Goldstein 
et al, as long as temperature or leukocyte count is abnormal. 
3.1.3. Severe sepsis 
Sepsis plus one of the following: 
• Acute respiratory distress syndrome OR 
• Two or more other organ dysfunctions. 
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• NOTE: severe sepsis + cardiovascular organ dysfunction =septic shock (see 
below) 
Respiratory dysfunction 
• PaO2/FIO2 < 300 in absence of cyanotic heart disease or preexisting lung disease, 
OR 
• PaCO2 >65 torr or 20 mm Hg over baseline PaCO2, OR 
• Proven need or >50% FIO2 to maintain saturation >92%, OR 
• Need for nonelective invasive or noninvasive mechanical ventilation Neurologic 
dysfunction 
• Glasgow Coma Score <11, OR 
• Acute change in mental status with a decrease in Glasgow Coma Score >3 points 
from abnormal baseline 
Hematologic dysfunction 
• Platelet count <80,000/mm3 or a decline of 50% in platelet count from highest 
value recorded over the past 3 days (for chronic hematology/oncology patients), 
OR 
• International normalized ratio >2 
Renal dysfunction 
• Serum creatinine >2 times upper limit of normal for age or 2-fold increase in 
baseline creatinine 
Hepatic dysfunction 
• Total bilirubin >4 mg/dL (not applicable for newborn) OR 
• ALT 2 times upper limit of normal for age 
It is the presence of bacteria, other infectious organisms, or toxins created by infectious 
organisms in the bloodstream with spread throughout the body. 
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3.1.4. Septic shock 
Sepsis and cardiovascular organ dysfunction. 
Cardiovascular dysfunction 
Despite administration of isotonic intravenous fluid bolus >40 mL/kg in 1 hr 
• Decrease in BP (hypotension) <5th percentile for age or systolic BP <2 SD below 
normal for age, OR 
• Need for vasoactive drug to maintain BP in normal range (dopamine >5 
microg/kg/min or dobutamine, epinephrine, or norepinephrine at any dose), OR 
• Two of the following 
o Unexplained metabolicacidosis:basedeficit >5.0mEq/L  
o Increasedarteriallactate >2timesupperlimitofnormal  
o Oliguria: urineoutput <0.5mL/kg/hr 
o Prolongedcapillaryrefill:>5secs 
o Coretoperipheraltemperaturegap>3°C 
3.2. CLABSI (CDC definition) 
Central line-associated BSI (CLABSI): A laboratory-confirmed bloodstream infection 
(LCBI) where central line (CL) or umbilical catheter (UC) was in place for >2 calendar 
days when all elements of the LCBI infection criterion were first present together, with 
day of device placement being Day 1, 
AND 
CL or UC was in place on the date of event or the day before. If the patient is admitted or 
transferred into a facility with a central line in place (e.g., tunnelled or implanted central 
line), day of first access is considered Day1. 
Must meet one of the following criteria: 
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1. Patient has a recognized pathogen cultured from one or more blood cultures and 
organism cultured from blood is not related to an infection at another site. 
2. Patient has at least one of the following signs or symptoms: fever (>38oC), chills, or 
hypotension 
AND 
positive laboratory results are not related to an infection at another site 
AND 
common commensal (i.e., diphtheroids [Corynebacterium spp. not C. diphtheriae], 
Bacillus spp. [not B. anthracis], Propionibacterium spp., coagulase-negative 
staphylococci [including S. epidermidis], viridans group streptococci, Aerococcus 
spp., and Micrococcus spp.) is cultured from two or more blood cultures drawn on 
separate occasions. Criterion elements must occur within a timeframe that does not 
exceed a gap of 1 calendar day. 
(See complete list of common commensals at http://www.cdc.gov/nhsn/XLS/master- 
organism-Com-Commensals-Lists.xls) 
3. Patient ≤1 year of age has at least one of the following signs or symptoms: fever 
(>38ºC core) hypothermia (<36ºC core), apnea, or bradycardia 
AND 
positive laboratory results are not related to an infection at another site 
AND 
common skin commensal (i.e., diphtheroids [Corynebacterium spp. not C. 
diphtheriae], Bacillus spp. [not B. anthracis], Propionibacterium spp., coagulase- 
negative staphylococci [including S. epidermidis], viridans group streptococci, 
Aerococcus spp., Micrococcus spp.) is cultured from two or more blood cultures 
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drawn on separate occasions. Criterion elements must occur within a timeframe that 
does not exceed a gap of 1 calendar day. 
(See complete list of common commensals at http://www.cdc.gov/nhsn/XLS/master- 
organism-Com-Commensals-Lists.xlsx) 
3.3. Scarlet Fever (positive throat swab, admitted) 
Scarlet fever is an infection that is caused by Group A streptococcal bacteria (S. 
pyogenes). The disease is characterized by a sore throat, fever, and a sandpaper-like rash 
on reddened skin. 
In the EUCLIDS study, scarlet fever (positive throat swab) is of interest and to be 
included. 
3.4. Gastroenteritis by salmonella (salmonellosis) 
Salmonellosis is a disease caused by the bacteria salmonella. It is usually characterized 
by acute onset of fever, abdominal pain, diarrhoea, nausea and sometimes vomiting. 
In the EUCLIDS study, gastroenteritis for salmonella (positive culture stool or blood?) is 
of interest and to be included. 
3.5. Endocarditis: 
It ́s an inflammation of one or more of the heart valves and lining tissues of the heart. 
Symptoms are nonspecific and include fever, chills, and weakness 
In the EUCLIDS study, bacterial endocarditis (positive culture) is of interest and to be 
included. 
Dukes Clinical Criteria for Diagnosis of Infective Endocarditis 
DEFINITE INFECTIVE ENDOCARDITIS  
Pathologic Criteria 
• Microorganisms: demonstrated by culture or histology in a vegetation, in a 
vegetation that has embolized or in an intracardiac abscess 
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• Pathologic lesions: vegetation or intracardiac abscess present, confirmed by 
histology showing active endocarditis 
Clinical Criteria (see below) 
• Two major criteria, OR 
• One major and three minor criteria, OR 
• Five minor criteria 
POSSIBLE INFECTIVE ENDOCARDITIS 
• One major criterion and one minor criterion OR 
• Three minor criteria  
REJECTED 
• Firm alternative diagnosis for manifestations of endocarditis, OR 
• Resolution of manifestations of endocarditis with antibiotic therapy for ≤ 4 days, 
OR 
• No pathologic evidence of infective endocarditis at surgery or autopsy, after 
antibiotic therapy for < 4 days, OR 
• Does not fulfill criteria above 
Definitions of Major and Minor Criteria Used in the Duke Schema for the Diagnosis 
of Infective Endocarditis (IE) 
MAJOR CRITERIA 
1. Positive blood culture for IE 
a. Typical microorganism consistent with IE from two separate blood cultures: 
• Viridans streptococci 
• Streptococcus bovis 
• HACEK group [a] 
• Staphylococcus aureus 
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• Community-acquired enterococci (without a primary focus) 
• Single positive blood culture for Coxiella burnetii or IgG antibody titer > 
1:800 
2. Evidence of endocardial involvement. 
a. Positive echocardiogram for IE, defined as: 
• Oscillating intracardiac mass on valve or supporting structures, in the path 
of regurgitant jets, or on implanted material in the absence of an alternative 
anatomic explanation 
• Abscess 
• New partial dehiscence of prosthetic valve 
b. New valvular regurgitation (worsening or changing of pre-existing murmur 
not sufficient) 
MINOR CRITERIA 
1. Predisposition: predisposing heart condition or intravenous drug use 
2. Fever: temperature ≥38.0°C 
3. Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic 
aneurysm, intracranial hemorrhage, conjunctival hemorrhages, and Janeway 
lesions 
4. Immunologic phenomena: glomerulonephritis, Osler nodes, Roth spots, and 
rheumatoid factor 
5. Microbiologic evidence: positive blood culture but does not meet a major 
criterion as noted above [b] or serologic evidence of active infection with organism 
consistent with IE 
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[a] HACEK: Haemophilus aphrophilus, Actinobacillus 
actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, 
Kingella kingae. 
[b] Excludes single positive cultures for coagulase-negative staphylococci 
and organisms that do not cause endocarditis. 
3.6. Influenza-like illness 
Sudden-onset fever (>38°C) with headache, myalgia, malaise and manifestation of URTI, 
such as cough, sore throat or rhinitis, in the absence of other diagnoses. 
3.7. Fever without source (FWS) 
Children with fever lasting for one week or less without adequate explanation after a 
careful history and thorough physical examination. 
It is also known as fever without localizing signs or fever without focus. 
3.8. Fever of unknown origin (FUO) 
Children with fever >38.3oC of at least 8 days' duration, in whom no diagnosis is apparent 
after initial outpatient or hospital evaluation that includes a careful history and physical 
examination and initial laboratory assessment. 
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Appendix: Causes of death for patients with SFI.  
 
The 7 patients with SFI who died were due to a decompensation of a chronic disease or a 
complication from the initial infection as follows: 
 
- Patient 1: acute necrotizing encephalopathy 
- Patient 2: pneumonia in the context of a complex congenital heart disease 
- Patient 3: lower respiratory tract infection on background of chronic lung disease 
- Patient 4: acute respiratory distress syndrome and pulmonary haemorrhage in the 
context of an RSV infection 
- Patient 5: cerebral infarction and cardiac failure in the context of a complex congenital 
disease operated 
- Patients 6: respiratory failure in a patient with Leigh’s disease 
- Patient 7: pulmonary haemorrhage in a patient with epilepsy, scoliosis, deformity of 
spine and lissencephaly 
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Appendix Figure 1: Differences between the identified organisms in whole cohort, 
those admitted to PICU and those admitted to wards by syndrome. GPC: gram 
positive cocci, GAS: Group A Streptococcus, GNR: gram negative rods, CoNS: 
Coagulase Negative Staphylococci. 
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Appendix Figure 2: Serum levels of (A) C-Reactive protein (CRP) and (B) 
neutrophils counts in different group of patients on admission. Data are expressed as 
mg/L for CRP and x109/L for neutrophils count.  
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Appendix Figure 3: Receiver operating characteristic curve of CRP, and neutrophil 
count in different settings. 
 
 
